Name | Moxetumomab |
---|
Description | Moxetumomab, a recombinant CD22-targeting immunotoxin, can be used for the research of hairy cell leukemia (HCL)[1][2]. |
---|---|
Related Catalog | |
References |
[2]. Sohita Dhillon. Moxetumomab Pasudotox: First Global Approval. Drugs. 2018 Nov;78(16):1763-1767. |
No Any Chemical & Physical Properties |